Classifications for carcinogenesis of antitumoral drugs.
The aim of this review is to support the medical staff engaged in tumor therapy with the carcinogenicity, mutagenicity, developmental toxicity classification of a large number of chemiotherapic drugs by national and international Agencies; it also gives their rationale and the few cases for which the classification varies among, for example, the European Union and the United States of America. A large list of such drugs, producers, commercial names, CAS numbers and chemical names is reported. This list is subject to changes for the quick development in this field: many drugs are retired and many more are introduced in clinical practice. The list is updated to the summer 2003 and retains many drugs which have more than one use or have limited use. The protection of the medical personnel using antitumor chemiotherapics can need retrospective epidemiological investigations and obsolete drugs are of importance for some of the past exposures.
Binetti
R
R
Inventario Nazionale delle Sostanze Chimiche, Dipartimento Ambiente e Connessa Prevenzione Primaria, Istituto Superiore di Sanità, Rome, Italy. binetti@iss.it
Costamagna
F M
FM
Marcello
I
I
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000737:chemistry / Q000145:classification*; D002273:Carcinogens / Q000009:adverse effects / Q000737:chemistry / Q000145:classification*; D005062:European Union; D006801:Humans; D038622:Internationality; D020407:Internet; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D002273:Carcinogens